RT Journal Article
SR Electronic
T1 Clinical Outcomes of Hydrogel Spacer Injection Space OAR in Men Submitted to Hypofractionated Radiotherapy for Prostate Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 3385
OP 3389
DO 10.21873/invivo.12637
VO 35
IS 6
A1 PIETRO PEPE
A1 MARIA TAMBURO
A1 MICHELE PENNISI
A1 DARIO MARLETTA
A1 FRANCESCO MARLETTA
YR 2021
UL http://iv.iiarjournals.org/content/35/6/3385.abstract
AB Background/Aim: To evaluate the clinical outcomes of men with prostate cancer (PCa) submitted to hydrogel spacer injection before hypofractionated radiotherapy (HRT). Patients and Methods: From April 2018 to April 2020, 32 patients with clinically localized PCa underwent hydrogel injection Space OAR before HRT to the prostate and seminal vesicle; the prescription dose was 60 Gy in 20 fractions, 5 days/week over 4 weeks. PSA levels, genitourinary (GU) and gastrointestinal (GI) toxicities, and sexual function were prospectively evaluated. Results: PSA levels at the median follow up of 15 months was 0.52 ng/ml; 28.1% vs. 78.1% patients had GI vs. GU Grade 0 acute toxicity and 93.7% vs. 0% had GI vs. GU Grade 0 late toxicity. Furthermore, 88.1% of patients kept pretreatment sexual potency. Conclusion: The use of the hydrogel Spacer OAR before HRT is useful for reducing acute and late GU and GI toxicities.